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Abstract
Background and purpose: Chest wall toxicity is observed after stereotactic body
radiation therapy (SBRT) for peripherally located lung tumors. We utilize machine
learning algorithms to identify toxicity predictors to develop dose–volume
constraints.
Materials and methods: Twenty‐five patient, tumor, and dosimetric features were
recorded for 197 consecutive patients with Stage I NSCLC treated with SBRT, 11 of
whom (5.6%) developed CTCAEv4 grade ≥2 chest wall pain. Decision tree modeling
was used to determine chest wall syndrome (CWS) thresholds for individual fea-
tures. Significant features were determined using independent multivariate methods.
These methods incorporate out‐of‐bag estimation using Random forests (RF) and
bootstrapping (100 iterations) using decision trees.
Results: Univariate analysis identified rib dose to 1 cc < 4000 cGy (P = 0.01), chest
wall dose to 30 cc < 1900 cGy (P = 0.035), rib Dmax < 5100 cGy (P = 0.05) and
lung dose to 1000 cc < 70 cGy (P = 0.039) to be statistically significant thresholds
for avoiding CWS. Subsequent multivariate analysis confirmed the importance of rib
dose to 1 cc, chest wall dose to 30 cc, and rib Dmax. Using learning‐curve experi-
ments, the dataset proved to be self‐consistent and provides a realistic model for
CWS analysis.
Conclusions: Using machine learning algorithms in this first of its kind study, we
identify robust features and cutoffs predictive for the rare clinical event of CWS.
Additional data in planned subsequent multicenter studies will help increase the
accuracy of multivariate analysis.
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1 | INTRODUCTION
Stereotactic body radiation therapy (SBRT), or stereotactic ablative
radiotherapy (SABR), is an increasingly used radiation modality for
the treatment of primary early‐stage1 and metastatic lung tumors.2
SBRT has been shown to provide effective local control with accept-
able toxicity.3 It is the preferred treatment modality for medically
inoperable stage I non‐small‐cell lung cancer (NSCLC) patients, and
there is emerging evidence and investigation regarding its role for
selected operable NSCLC patients,4–6 as well as for stage I small‐cell
lung cancer patients.7,8
The chest wall has been identified as an organ at risk for SBRT,
with chest wall toxicities of any grade ranging from 2% to 45% fol-
lowing SBRT.9–12 Radiation‐related chest wall toxicity can result from
radiation‐induced rib fracture or chest wall syndrome (CWS). In the
absence of rib fracture, CWS is caused by radiation‐induced neu-
ropathy of the intercostal nerves or nerve branches, chest wall
edema, chest wall fibrosis, or hairline rib fractures not clearly visible
on imaging.12–14
There is currently a paucity of data on standard dose–volume
constraints for the chest wall, with no clear consensus on how to
balance target coverage versus chest wall/rib sparing or how factors
like fractionation impact CWS. A commonly used constraint is chest
wall dose to 30 cc < 30 Gy,15 yet there is no prospectively validated
data to support this threshold. There have been efforts in recent
years to identify the risk factors for rib fractures and CWS and to
refine the clinical and dosimetric predictors of chest wall toxicity
using dose–response models.15–18
One challenge in evaluating predictive factors for CWS is the
low and varying range of events observed.14,17,19 Machine learning
has previously been used in radiation oncology for a variety of prob-
lems, from quality assurance to outcome prediction.20–26 In circum-
stances where the event being analyzed is relatively uncommon,
machine learning algorithms are advantageous in magnifying events.
This is achieved by developing models that can learn from and make
predictions of a given dataset. Examples include hierarchical cluster-
ing models which can iterate quickly through different features and
cutoffs in order to identify potentially predictive factors based on
how effectively events are separated from nonevents.26 The use of
these computational algorithms to mine raw data can filter out noise
and identify the pertinent factors when the number of events is
smaller than the number of features. This current study, the first of
its kind, utilizes such algorithms to identify specific dosimetric
thresholds predictive for CWS in 197 consecutive patients with
Stage 1 NSCLC treated with SBRT.
2 | MATERIALS AND METHODS
2.A | Patient inclusion
This study was approved by our institutional review board. A cohort
of 197 consecutive patients diagnosed with Stage I NSCLC and trea-
ted with SBRT from June 24, 2009, to July 31, 2013, to allow for
adequate toxicity follow‐up was identified. All patients were treated
to a biologically effective dose (BED) of ≥ 100 Gy in one of four
fractionation schemes: (a) 20 Gy × 3 fractions, 12.5 Gy × 4 fractions,
10 Gy × 5 fractions, or 7.5 Gy × 8 fractions. All patients were
planned with a constraint goal to keep 30 cc of the chest wall to
<30.0 Gy. Twenty‐five parameters (termed features in the machine
learning analysis) suspected of a correlation or previously
reported10,12,13,15,17,27–31 to associate with CWS were analyzed,
including patient and tumor characteristics and dosimetric features
were recorded for each patient. Toxicities were assessed using
CTCAEv4 criteria for chest wall pain, where Grade 1 represents mild
pain, Grade 2 represents moderate pain limiting instrumental activi-
ties of daily living (ADL), and Grade 3 represents severe pain limiting
self‐care ADL.
2.B | Feature definition
Twenty‐five features were analyzed in this study. They were classi-
fied in two subsets: (a) highly important features (n = 10) and (b)
important features (n = 15) by a thoracic radiation oncologist spe-
cializing in lung SBRT. Highly important features were features
judged to likely correlate to CWS based on the published literature
and clinical judgment. The important features group included those
hypothesized to be potentially clinically correlated with CWS with-
out any appreciable prior published data. The evaluated features
(Table 1) were as follows.
2.B.1 | Highly important features
Highly important features consist of chest wall dose to 30 cc, rib
dose to 1 cc, rib dose max, medically inoperable versus patient refu-
sal, dose per fraction, age, body mass index, tumor size (cm), PTV
volume (cc), and age at first fraction.
2.B.2 | Important features
Important features consist of total dose, diabetes (Y/N), diffusion
capacity of the lung for carbon monoxide (DLCO adj%), forced expi-
ratory volume (FEV1(L)), decadron/prednisone use, TNM status,
stage, histology, lung mean dose, lung dose to 1000 cc, lung dose to
1500 cc, lung volume receiving 20 gy, lung volume receiving 15 gy,
lung volume receiving 10 gy, and number of fractions.
All dosimetric indices were calculated with heterogeneity correc-
tions, using the analytical anisotropic algorithm (AAA), Eclipse Ver-
sion 11.0 (Varian Medical Systems, Palo Alto, CA, USA).
2.C | Univariate analysis
Univariate CWS thresholds for each feature collected were gener-
ated to split the patient population into high‐ and low‐risk subpopu-
lations. These thresholds were determined using decision stumps
(simple univariate thresholds) implemented in Matlab R2015a (Math-
Works Inc., Natick, MA, USA). In all cases, the deviance was used to
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measure how far the decision tree is from the target output. It is a
smoother version of the classification error and provides a measure-
ment of the quality of the description provided.32 Each threshold
was characterized by the probability of splitting out patients with
and without CWS into the appropriate subpopulations. In addition, a
generalization score was determined for each threshold, which was
defined as the ratio of true positives for out‐of‐sample to in‐sample
data. A cutoff of >0.75 was used for the generalization score, mean-
ing a similar split of the data would result at least 75% of the time.
The generalization score is used to characterize out‐of‐sample per-
formance of the univariate dosimetric thresholds, and it quantifies
how well these thresholds should perform for data that the algo-
rithm has not encountered.26 This analysis was performed under the
conditional assumption that the true distribution of patients satisfy-
ing the threshold is represented by the patients not developing
CWS.
2.D | Multivariate analysis
Two different algorithms were considered: decision trees, for inter-
pretability, and Random forests, for accuracy.33–35 Decision trees
partition the data into a disjoint number of subpopulations and make
a constant prediction at each subpopulation. Random forests predict
outcomes by averaging the output of hundreds of decision trees.36
For specifics about these algorithms, the readers are referred to
“The Elements of Statistical Learning,” a comprehensive book about
machine learning.36 In this work, the complexity of the models for all
algorithms was controlled by choosing hyperparameters (global con-
stants that control the complexity of the algorithms such as the
number of times data are allowed to be partitioned in a decision
tree) that minimized the leave‐one‐out cross‐validation of the
deviance. Leave‐one‐out cross‐validation refers to a method where
one observation is left out of the dataset, and then performing train-
ing on the remaining observations and predicting the observation
that the algorithm has not seen. Specifically, the complexity of the
decision tree was optimized through the use of minimum number of
observations per node (Min Number per Node). Smaller node sizes
result in complex trees that do well in explaining the training dataset
with which the algorithm is initially presented but may result in sub-
optimal results with the testing dataset. This hyperparameter con-
trols the number of observations a terminal node must have before
attempting a split. As our goal was to identify the thresholds that
best predict CWS in future patients, we tested various training sets
(10 training sets in a 10 K‐fold experiment) in order to select hyper-
parameter values that minimized the testing error.
Two additional analyses were performed to control for overfit-
ting. First, the Min Number per Node was changed from 50 to 80 in
steps of 5. Second, for each hyperparameter, a random subsampling
of the patient population was performed where a predefined number
of patients ranging from 158 to 197 patients would be randomly
selected from the data set. One hundred iterations were performed,
and an aggregate decision tree was developed. All features that were
selected at least 10% of the time were compared to the maximally
selected feature.
The complexity of Random forests was controlled by selecting
the maximum number of splits allowed per individual tree and the
number of variables randomly subsampled. Unless otherwise speci-
fied, 500 individual decision trees were combined when Random for-
est was used. The default hyperparameter, the square root of the
number of features, was used for the number of feature subsamples
in Random forests. In all cases, artificial equal prior probabilities,
which is where the initial weights of the observations are up‐
sampled for the minority event (e.g., development of CWS) and
under‐sampled for the majority event (e.g., absence of CWS), such
that their sum would be equal, were used to avoid the inherent bias
in the algorithms due to the skewed dataset. One hundred iterations
were performed, and we identified features that have an out‐of‐bag
importance, which is at least 10% of the maximally selected feature.
The out‐of‐bag importance, as defined by Breiman, is an unbiased
estimator of the predictive value of a feature, which uses randomly
generated training sets by sampling with replacement.33,34
2.E | Learning‐curve experiments
In order to test the self‐consistency of our data, Learning‐curve
experiments were performed. In a Learning‐curve experiment,
TAB L E 1 List of all features selected for analysis. Each feature
selected for analysis is listed and broken down by classification as a
highly important or important feature.
Highly important
features
Chest wall dose to 30 cc
Rib dose to 1 cc
Rib dose max
Medically inoperable vs patient refusal
Dose per fraction
Age
Body mass index
Tumor size (cm)
PTV volume (cc)
Age at first fraction
Important features Total dose
Diabetes (Y/N)
Diffusion capacity of the lung for carbon
monoxide (DLCO adj%)
Forced expiratory volume (FEV1(L))
Decadron/prednisone use
TNM status
Stage
Histology
Lung mean dose
Lung dose to 1000 cc
Lung volume receiving 10 Gy
Number of fractions
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different numbers of patients are subsampled from the original data-
set, models are built using the subsampled data assumed to be train-
ing data, and then the training and testing errors are determined.
3 | RESULTS
3.A | Patient characteristics and identification of
features and thresholds predicting CWS
Twenty patients were treated with a 20 Gy × 3 fractions regimen,
102 patients were treated using a 12.5 Gy × 4 fractions, 66
patients were treated using 10 Gy × 5 fractions, and 12 patients
were treated using a 7.5 Gy × 8 fractions regimen. In our dataset,
11 patients developed Grade ≥2 chest wall toxicity. A univariate
analysis to identify optimal patient separation thresholds for CWS
development was performed on the initial set of 10 highly impor-
tant and 15 important patient features. This analysis revealed three
Highly important features, including chest wall dose to 30 cc
(P = 0.035), rib dose to 1 cc (P = 0.01), and rib dose max
(P = 0.05), and one important feature [lung dose to 1000 cc
(P = 0.039)], as statistically significant (Table 2). These four features
and their corresponding thresholds all met a generalization score of
>0.75.
3.B | Decision tree modeling
The decision tree analysis revealed that when evaluating different
node sizes ranging up to 100 patients per terminal node, values of
this hyperparameter ranging from 50 to 80 patients per terminal
node produce similar results in the testing dataset, with local minima
observed at 50 patients per node and 80 patients per node (Fig. 1).
When evaluating terminal node sizes above 80 patients per node,
the decision trees become overly simplified, resulting in the training
and testing dataset errors being similar.
Decision trees with node sizes of 50 and 80 patients per termi-
nal node are shown in Fig. 2. In the scenario where the Min Number
per Node = 50, our machine learning algorithm identifies rib dose to
1 cc < 4000 cGy as an important feature and dose threshold, with
only one of 93 (1.1%) patients below this threshold developing
CWS, as compared with 10 of 104 (9.6%) patients exceeding this
threshold. With these parameters, a second split was generated,
demonstrating that a smaller PTV volume is associated with a higher
incidence of CWS [Fig. 2(a)]. If instead, the Min Number per Node =
80, only the first split is obtained [Fig. 2(b)].
3.C | Feature robustness and data consistency
When introducing variation components of differing nodal size and
random subsampling of the population to test for feature robustness,
only rib dose to 1 cc and chest wall dose to 30 cc were selected as
features that influence development of CWS (Fig. 3). Random forest
analysis performed as part of a second and separate analysis of
robustness also identified rib dose to 1 cc and chest wall dose to
30 cc as predictors of CWS. Rib Dmax was additionally identified as
a potential predictor for CWS (Fig. 4), whereas PTV volume was
excluded.
Using learning‐curve experiments with different hyperparameters,
we found that as patient number in the training set increases, the
training error increased and the testing error decreased. The learn-
ing‐curve experiments established that our patient dataset is likely to
provide a true representation of the wider population with regard to
developing CWS (Fig. 5). This data consistency verification confirms
accepting the previously identified CWS predictors of rib dose to
1 cc < 4000 cGy, chest wall dose to 30 cc < 1900 cGy, and rib
Dmax < 5100 cGy (all P < 0.05).
4 | DISCUSSION
There is scarcity of clear literature and guidance on dosimetric
constraints for CWS. This study used a cohort of 197 consecutive
patients with Stage I NSCLC treated with SBRT to identify clini-
cally relevant predictive features. In this cohort, 11 (5.6%) patients
developed CTCAE v4 grade ≥2 chest wall pain. Prior studies sug-
gest rates of CWS, or chest wall pain without evidence of rib
fracture, range from 2% to 8%14,17,19 after SBRT, consistent with
our observations. Conventional analyses struggle to identify mean-
ingful clinically relevant thresholds for predicting toxicity due to
the low number of absolute events. Machine learning algorithms
are generally well suited to this challenge, given their advantages
in parsing large datasets in order to robustly stratify out rare
events.37
Prior efforts investigating predictors for chest wall toxicity are
generally conflicting or inconclusive on the relative importance of
risk factors, likely due to the limited number of patients and events
TAB L E 2 Significant features identified on univariate analysis.
Features with a CWS threshold with P < 0.05 (without adjustment
for multiple comparisons) and generalization value > 0.75. The
number of patients in each subgroup by feature threshold and the
number and percentage of patients developing CWS in each
subgroup are listed for reference. All features had missing values;
therefore, the number of patients is <197 for each.
Feature Thresholds Subpopulations risksa P value
Rib dose
to 1 cc
<4000 cGy (N = 83, 1 CWS event; 1.2%) vs
(N = 80, 8 CWS events; 10.0%)
0.010
Chest wall
dose
30 cc
<1900 cGy (N = 44, 0 CWS events; 0%) vs
(N = 134, 11 CWS events;
32.4%)
0.035
Lung dose
to 1000
cc
<70 cGy (N = 70, 1 CWS event; 1.4%) vs
(N = 126, 10 CWS events;
7.9%)
0.039
Rib Dmax <5100 cGy (N = 65, 1 CWS event; 1.5%) vs
(N = 98, 8 CWS events; 8.2%)
0.050
aPatient numbers do not add to 197 due to missing values present for
select parameters.
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assessed. A subset of prior studies of chest wall toxicity15,16 have
suggested that within the commonly used total dose and fractiona-
tion schemes for SBRT, dosimetric predictors do not result in signifi-
cantly different rates of toxicity. However, this does not imply that
rib and chest wall doses can be simply disregarded since (a) CWS
can result without the clinical appearance of rib fractures and (b)
increasing risk may still occur with increasing dose in a continuous
fashion.18 Other prior studies have examined factors including rib
Dmax, rib dose to 0.5 cc, 2 cc, rib V30, V40, chest wall Dmax, chest
wall dose to 8 cc, and chest wall V30, without clear indication of the
relative superiority or inferiority of one of these dosimetric factors
relative to the others.9,13,27,29,38,39 Global Dmax and fraction size are
also suggested to be important indicators of toxicity, with higher
rates of radiation‐induced rib fracture of ~50% for DMax > 54 Gy
and fraction size >8 Gy.16 Regarding the chest wall specifically, con-
straints of V30 Gy < 70 cc,12 V30 Gy < 35 cc,13 and D30 cc < 30
Gy have been recommended.15 Kimsey et al. examined chest wall
tolerance in SBRT and suggest that the D70 cc is an important fac-
tor to consider dosimetrically.15
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In this study, we analyzed 25 patient features, both dosimetric
and nondosimetric. Similar to the published literature, we found that
rib dose29 and chest wall dose13 are important dosimetric features.
Decision trees were considered the baseline algorithm because of
the ability to produce models that are clinically interpretable and
could be validated according to prior clinical knowledge. Random
forest was used to evaluate feature importance and to generate and
explore additional hypotheses. By separating the data into training
(data used to create the models) and testing (data used to evaluate
the performance of the model and not seen during training) proper
estimation of the error expected for the algorithm could be estab-
lished. Training and testing errors refer to errors calculated on these
datasets. In addition, by using interpretable algorithms like decision
trees (those that produced models that clinical practitioners can
understand) and black box algorithms (those that produce models
that cannot be easy understood but are potentially more accurate)
like Random forests that combine the input of hundreds of trees into
one prediction different hypothesis and important features can be
automatically selected.33,35,36,40 If the data are self‐consistent, then
the training error increases along with the number of patients used
to build the model. Conversely, if true knowledge is acquired from
the data, then the testing error will decrease with the number of
patients used for training.
Our final model, which combines the results of the baseline anal-
ysis using decision trees and is supplemented by the results of Ran-
dom forests, specifically identify a cutoff of rib dose to
1 cc < 4000 cGy, chest wall dose to 30 cc < 1900 cGy, and rib
Dmax < 5100 cGy as important prognosticators (Table 2, Figs. 3 and
4). As the large majority of the patients in the data set were treated
using 10 Gy × 5 or 12.5 Gy × 4 fractionation schemes (85%), the
dosimetric predictors derived from this study are most applicable to
patients treated with either of these regimens.
While machine learning is a potentially powerful tool, indiscrimi-
nate use also has the potential to result in erroneous or invalid
results. In this study, we employ different hyperparameter settings
and utilize several different algorithms to validate findings and filter
out spurious results. Through use of multiple permutations, random
subsampling, variation in node size, and robust decision tree
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0 20 40 60 80 100 120 140 160 180 200
0.1
0.2
0.3
0.4
0.5
0.6
0.8
0.9
Number of Samples
Er
ro
r
Training vs Testing Error
 
 
Testing Error
Training Error
0.7
F I G . 5 . Learning curve for analysis
dataset. Out‐of‐sample deviance estimated
for training and testing data for different
number of observations used for training.
All points refer to the mean value over
100 iterations.
544 | CHAO ET AL.
modeling, we identified the features that are likely to truly con-
tribute to the development of CWS. These data verification method-
ology allowed us to filter out an initial result, suggesting lower PTV
volumes contributed to increased CWS development [Fig. 2(a)]. Our
analysis also reliably reproduced rib dose to 1 cc as an important
feature, as well as confirming chest wall dose to 30 cc and rib Dmax
as robust features (Figs. 3 and 4).
Our findings are consistent with prior analyses illustrating the
importance of chest wall dose, but this analysis utilizes the added
advantage of machine learning to assign increased importance to a
specific chest wall dosimetric factor. This has the potential to
allow for informed, evidence‐backed clinical decision making in
scenarios where two or more planning goals may be mutually
exclusive and priority must be given to one. A prior study by Thi-
bault et al.17 suggests that location alone predicts for rib fracture,
with the incidence increased in peripherally located tumors. Their
efforts showed no significant predictive dosimetric criteria, with
the only other predictive clinical factor being the presence of
osteoporosis. Our data confirm the importance of tumor location,
as it follows that radiation dose in proximity to the chest wall
and ribs are necessary for the development of CWS. However,
our findings suggest that tumor location may be a surrogate for
dose received by the ribs and chest wall, which are the true dri-
vers of the development of CWS. Due to the relative rarity of
events, our machine learning approach may have allowed for us
to identify potentially relevant dosimetric factors that were not
identified by Thibault et al.
A potential shortcoming of this study, and other similar studies,
lies with the fact that CWS grading is inherently subjective. This is a
potential bias intrinsic to analyses of CWS. Our study is likewise
unable to compensate for this underlying subjectivity. Another limi-
tation of our study is that an exhaustive analysis of all possible vari-
ables and thresholds is prohibitive, despite utilizing machine learning.
With the chest wall constraints, we evaluated the commonly
employed constraint of chest wall dose to 30 cc. A weakness of this
approach is whether this choice represents the ideal volumetric con-
straint. Future investigations assessing continuous volumetric model-
ing of the chest wall constraint in addition to continuous dose
modeling are warranted. This could likewise be employed to other
relevant thoracic structures like the rib, akin to a prior effort by Pet-
terson et al.,29 and lung dose. Expanded datasets in future analyses
will add to the robustness of our findings, and future work will focus
on external validation in a multicenter analysis.
5 | CONCLUSIONS
The strength of this study, the first of its type, is in the use of
machine learning heuristic clustering analysis to identify factors in a
continuous fashion that would predict both for and against CWS by
incorporating patient‐ and tumor‐related variables and dosimetric
factors. From our analysis, we conclude that in patients treated with
SBRT using common and standard fractionation schemes
(4 × 12.5 Gy, 5 Gy × 10), providers should attempt to keep the rib
dose to 1 cc <4000 cGy, chest wall dose to 30 cc < 1900 cGy, and
rib Dmax < 5100 cGy in order to mitigate CWS. These novel and
clinically meaningful metrics provide a guide for treatment planning
of SBRT and contribute to the knowledge base for patient counsel-
ing and informed consent.
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